Drug intelligence / Profile preview

PF-07314470

Development stage: Unknown
Lead developer: Pfizer
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

PF-07314470 is a bispecific antibody developed by Pfizer, currently in phase 1 clinical trials. It is administered as a subcutaneous injection and is being evaluated for safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers. The drug targets both Interleukin-27 (IL-27) and Interleukin-6 receptor subunit beta (IL6RB), acting as an inhibitor of IL-27 and an antagonist of IL6RB. Its primary therapeutic focus appears to be immune system diseases such as inflammatory bowel diseases, though the specific indication under investigation has not been publicly disclosed[1][2][3][4].

Targets

IL-27 (Interleukin-27)IL6ST (Interleukin-6 receptor subunit beta)

Beyond the preview

Go deeper on PF-07314470.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07314470.

Explore the full profile